on-invasive localized positive electrostatic therapy of malignant cancer tumors by suppression of anti-apoptotic enzymes and expression of apoptotic ones

Iran Nano Fund0 个研究点目标入组 50 人开始时间: 待定最近更新: 2019年11月5日

适应症

试验速览

暂无简介。

•Patients who have different types of cancer with solid tumors.
•Patients who the biopsy of their tumors approved that the tumors are malignant.
•Patients who their malignant tumors are not obey the normal cellular pathways of the tissue.
•Patients with malignant tumors and highest levels of invasion are more appropriate for receiving treatment (i.e. triple negative breast cancer).
•Patients who their tumors are not too deep and not too far from the surface of the body.
•Pathological or radiological evidence of malignancy
•Pathological or radiological evidence of progression of the disease despite classical treatments
•Pathological or radiological evidence of recurrence of the disease despite classical treatments
•At least 3 months life expectency
•Patients with end-stage cancer who oncologists confirm that they did not profit from an alternative treatment, can include the study as a palliative therapy.

•Patients who do not have appropriate general condition and need intensive care.
•Patients with tumors which tumor cells are obey the normal cellular pathways of the tissue.
•Patients who have different types of cancer which have no solid tumors.
•Patients with benign tumors or the types of malignant tumors which are not invasive enough.
•Patients who their tumors are deep and far from the surface of the skin.
•Coagulation disorders (INR>1.5)
•Platelets<150000
•Neutropenia (neutrophil<1500)
•Anemia (Hemoglobin<12)
•Acute Infection
•Patients with pacemaker or any types of cardiac arrhythmia
•Abnormal biochemistry or electrolyte of the serum.

发起方

Iran Nano Fund